Jonathan Condit, DO
Family Medicine · Muncie, INNPI 1194803189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,618 of the $9,119 with a category attached, or 72.6%. 28 manufacturers reported payments, led by AbbVie at 42.5% of the total. Reporting peaked in 2020 at $4,194 and has fallen 82.9% since, to $716 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$2K
- Lilly USA, LLC$645
- Novo Nordisk$301
- GSK$280
- Teva Pharmaceuticals USA, Inc.$215
- plus $1K from 22 others
Across 1,538 payments — averaging $1040.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$873K
- Novo Nordisk AS$412K
- Novartis$105K
- AstraZeneca$78K
- AbbVie$68K
- Astrazeneca UK Limited$29K
- plus $34K from 6 others
What the payments were for
- Speaking & faculty fees$1,70019%
- Travel & lodging$7678%
- Food & beverage$6,61873%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $3,878 |
| AstraZeneca | 72 | $2,431 |
| Lilly USA, LLC | 42 | $645 |
| Novo Nordisk | 12 | $301 |
| GSK | 20 | $280 |
| Teva Pharmaceuticals USA, Inc. | 2 | $215 |
| Pfizer | 12 | $213 |
| Johnson & Johnson | 11 | $166 |
| Sanofi-aventis U.S. LLC | 9 | $148 |
| Amarin Pharma, Inc. | 6 | $130 |
| Amgen(2 entities) | 7 | $107 |
| Merck | 6 | $104 |
| Boehringer Ingelheim | 3 | $65 |
| Mylan Specialty L.p. | 3 | $51 |
| Exact Sciences | 3 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Medtronic | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| IBSA Pharma Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,119 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $210,718 |
| EliquisApixaban | 140 | $193,843 |
| FarxigaDapagliflozin Propanediol | 128 | $142,261 |
| MounjaroTirzepatide | 59 | $117,912 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $117,546 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $89,594 |
| JardianceEmpagliflozin | 65 | $89,144 |
| JanuviaSitagliptin Phosphate | 43 | $60,608 |
| XareltoRivaroxaban | 47 | $59,590 |
| EntrestoSacubitril/Valsartan | 22 | $38,381 |
| UbrelvyUbrogepant | 19 | $35,565 |
| VraylarCariprazine Hcl | 17 | $29,161 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $28,153 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $27,516 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $27,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $301 | $210,718132 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $2,431 | $209,454243 claims |
| PfizerEliquis | $213 | $193,843140 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $280 | $129,426143 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $65 | $118,341100 claims |
| Lilly USA, LLCMounjaro | $645 | $117,91259 claims |
| Johnson & JohnsonXarelto, Invokana | $166 | $84,01862 claims |
| MerckJanuvia, Janumet | $104 | $78,10059 claims |
| AbbVieUbrelvy, Vraylar, Synthroid | $3,878 | $72,268119 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $8,170464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Muncie
- Jeffrey HiltzMuncie$177K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.